Methods and compositions for dissolving or solubilizing therapeutic agents.

Abstract

To provide methods and compositions for dissolving or solubilizing therapeutic agents.SOLUTION: The invention provides pharmaceutical compositions comprising a dry medicament. The dry medicaments can be rapidly dissolved, solubilized, and / or reconstituted to be delivered to a subject. The present invention provides methods of preparing a medical solution. The medical solution can be prepared by mixing a pharmaceutical composition as described herein with a first liquid. In some embodiments, a dry pharmaceutical composition comprises a combination of a dry medicament and one or more dry pH adjusting agents. In some embodiments, the dry pharmaceutical composition can be reconstituted into a solution by mixing the dry pharmaceutical composition with a first solution. In some embodiments, the first solution has a pH that rapidly dissolves the dry medicament.SELECTED DRAWING: None

Description

[Technical Field]

[0001] Related Applications This invention claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 62 / 094,063, filed December 18, 2014, the entire contents of which are incorporated herein by reference. [Background technology]

[0002] Individuals suffering from certain medical conditions often need to keep an auto-injector or pre-filled syringe nearby to address their medical needs: insulin pens for those with diabetes, epinephrine auto-injectors for those with food and insect sting allergies, and antidotes for soldiers at risk of exposure to chemical and / or biological toxins on the battlefield, to name a few.

[0003] Exposure to certain substances, such as peanuts, shellfish, bee venom, certain drugs, and toxins, can trigger allergic reactions in susceptible individuals. Such allergic reactions can lead to anaphylactic shock, which can cause a sudden drop in blood pressure, hives, and / or severe airway narrowing, potentially becoming a life-threatening condition. A susceptible individual's response to an allergen can gradually or suddenly increase or decrease over time, leaving a significant proportion of these susceptible individuals in need of solutions to mitigate the effects of anaphylactic shock. Responding promptly to mitigate the effects of such exposure can prevent injury and / or death. For example, in certain circumstances, an injection of epinephrine (i.e., adrenaline) can provide substantial and / or complete relief from the allergic reaction.

[0004] With respect to allergies, for example, allergic reactions may occur in locations physically far from the nearest hospital or medical facility. For example, bee stings are more likely to occur outdoors than indoors. Foods containing peanuts are more likely to be served to individuals away from controlled home environments, such as baseball stadiums.

[0005] Because emergency medical facilities may not be available when an individual suffers an allergic reaction, some individuals carry a medication delivery device, such as an auto-injector, to rapidly self-administer epinephrine in response to an allergic reaction. Having an epinephrine auto-injector nearby allows for emergency intervention after exposure to an allergen to reduce and / or reverse the life-threatening side effects of anaphylaxis.

[0006] For patients who need to carry epinephrine auto-injectors, the thermal stability profile of the medication can be an issue. Patients must ensure that their medication is not exposed to excessive heat or cold outside of controlled room temperature. Otherwise, the medication can rapidly degrade, resulting in a drug that does not have the recommended efficacy to treat an anaphylactic shock episode. Summary of the Invention [Means for solving the problem]

[0007] The present invention provides dry pharmaceutical compositions (e.g., dry powder compositions) that can be rapidly reconstituted into a liquid formulation for delivery (e.g., via injection) to a subject, e.g., a human subject. In some embodiments, the dry pharmaceutical composition comprises a combination of a dry pharmaceutical and one or more dry pH adjusting agents. In some embodiments, the dry pharmaceutical composition can be reconstituted into a liquid formulation by mixing with a first solution. In some embodiments, the first solution has a pH that rapidly dissolves the dry pharmaceutical. In some embodiments, the dry pH adjusting agent dissolves more slowly than the dry pharmaceutical, resulting in a pH adjustment of the solution after dissolution of the dry pharmaceutical. Aspects of the present disclosure are useful for facilitating rapid dissolution of a dry pharmaceutical (e.g., epinephrine) at a pH that may be physiologically unacceptable, followed by a slower pH change to a physiologically acceptable range. According to the present disclosure, this process can be achieved in a single step by mixing a solution with a dry combination of the appropriate pharmaceutical and pH adjusting agent.

[0008] In some embodiments, the dry pharmaceutical composition comprises one or more pharmaceutically acceptable carriers. Further provided herein are kits and systems comprising the pharmaceutical compositions as described herein. According to aspects of the invention, dry pharmaceutical compositions have several advantages over liquid compositions, including increased stability (e.g., extended shelf life, potency and / or chiral stability) over extended periods of time and when exposed to temperature changes.

[0009] In some aspects, the present disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of a dry pharmaceutical and one or more pH adjusting agents (e.g., one or more dry pH adjusting agents). In some embodiments, the pH adjusting agent is solid. In some embodiments, the pharmaceutical composition reaches a first pH after being mixed with a first liquid. In some embodiments, the first pH is less than about 7.0. In some embodiments, the first pH is less than about 6.0. In some embodiments, the first pH is less than about 5.0. In some embodiments, the first pH is less than about 4.0. In some embodiments, the first pH is less than about 3.0. In some embodiments, the first pH is less than about 2.0. In some embodiments, the first pH is less than about 2.2. In some embodiments, the first pH is between about 2.2 and about 5.0. In some embodiments, the first pH is less than about 1.0. In some embodiments, the first pH is greater than about 7.0. In some embodiments, the first pH is greater than about 8.0. In some embodiments, the first pH is greater than about 9.0. In some embodiments, the first pH is greater than about 10.0. In some embodiments, the first pH is greater than about 11.0. In some embodiments, the first pH is greater than about 12.0. In some embodiments, the first pH is greater than about 13.0. In some embodiments, the dry medicament is more soluble in the first liquid than the one or more dry pH adjusters. In some embodiments, the dry medicament forms a readily solubilized salt when mixed with the first liquid. For example, free base epinephrine forms a more soluble salt when mixed with a first liquid containing an acid.

[0010] In some embodiments, the pharmaceutical composition or the solution formed from the dry medicament and the first liquid is further contacted with one or more pH adjusters to reach a second pH. In certain embodiments, the second pH is a physiologically acceptable pH. In some embodiments, the second pH is a physiological pH. In some embodiments, the second pH is about 2.2 to about 5.0, and the dry medicament is epinephrine. In some embodiments, the second pH is about 4.2 to about 5.3, and the dry medicament is sumatriptan. In some embodiments, the second pH is about 0.1 to about 3.0 or 9.5 to 13.5, and the dry medicament is glucagon.

[0011] In another aspect, provided herein is a medical kit comprising a pharmaceutical composition as described herein and a first liquid.

[0012] In another aspect, the present disclosure provides a method for preparing a medical solution, comprising mixing a pharmaceutical composition as described herein with a first liquid. In certain embodiments, the pharmaceutical composition is administered to a subject via a medical device. In certain embodiments, the pharmaceutical composition is disposed in a first chamber of the medical device. In certain embodiments, the first liquid is disposed in a second chamber of the medical device. Prior to injection, the pharmaceutical composition is mixed with the first liquid to dissolve the dry pharmaceutical, followed by pH adjustment with one or more dry pH adjusters to reach a physiologically acceptable pH. The dissolution and pH adjustment process is generally completed within less than 5 minutes. In some embodiments, the dissolution and pH adjustment process is generally completed within less than 1 minute. In some embodiments, the dissolution and pH adjustment process is generally completed within less than 30 seconds. In some embodiments, the dissolution and pH adjustment process is generally completed within less than 10 seconds. In some embodiments, the dissolution and pH adjustment process is generally completed within less than 5 seconds. In some embodiments, the dissolution and pH adjustment process is generally completed within less than 1 second. In certain embodiments, the medical device is an automatic injector.

[0013] In certain embodiments, the pH adjusting agent is completely separated from the dry medicament. In certain embodiments, the pH adjusting agent is a particle different from the particle of the dry medicament. In certain embodiments, the pH adjusting agent is a particle associated with the particle of the dry medicament. In certain embodiments, the pH adjusting agent is a particle within the particle of the dry medicament. In certain embodiments, the pH adjusting agent is a particle embedded in the particle of the dry medicament. In certain embodiments, the particle sizes of the pH adjusting agent and the dry medicament are different. In certain embodiments, the particle sizes of the pH adjusting agent and the dry medicament are similar. In certain embodiments, the pH adjusting agent dissolves more slowly than the dry medicament.

[0014] These and other aspects of the present application are illustrated by the following non-limiting figures and explained in the detailed description. In an embodiment of the present invention, for example, the following items are provided: (Item 1) A pharmaceutical composition comprising a therapeutically effective amount of a dry medicament and one or more pH adjusting agents. (Item 2) Item 1, wherein the one or more pH adjusting agents are solid. (Item 3) 3. The pharmaceutical composition according to item 1 or 2, which reaches a physiologically acceptable pH after mixing with the first liquid. (Item 4) 4. The pharmaceutical composition of claim 3, wherein the dry medicament is more soluble in the first liquid than the one or more pH adjusting agents. (Item 5) 4. The pharmaceutical composition of claim 3, wherein the dry medicament is not associated with the one or more pH adjusting agents. (Item 6) 4. The pharmaceutical composition according to item 3, wherein the dry medicament and the one or more pH adjusting agents are different particles. (Item 7) 7. The pharmaceutical composition according to item 6, wherein the dry medicament is in particles smaller than the one or more pH adjusting agents. (Item 8) 8. The pharmaceutical composition of claim 7, wherein the particles of the dry medicament dissolve faster than the particles of the one or more pH adjusting agents. (Item 9) 8. The pharmaceutical composition according to item 7, wherein the particles of the dry medicament have a size of about 1 μm to about 30 μm. (Item 10) 8. The pharmaceutical composition according to item 7, wherein the particles of the one or more pH adjusting agents have a size of about 35 μm to about 100 μm. (Item 11) 4. The pharmaceutical composition according to item 3, wherein the pH adjusting agent is coated with one or more layers of a pharmaceutically acceptable carrier. (Item 12) 4. The pharmaceutical composition according to item 3, wherein the pH adjusting agent is coated with one or more layers of a pharmaceutically acceptable polymer. (Item 13) 13. The pharmaceutical composition according to any one of items 11 to 12, wherein the pH adjusting agent is released after dissolution of the dry medicament in the first liquid. (Item 14) 4. The pharmaceutical composition of claim 3, wherein the dry pharmaceutical is associated with the pH adjusting agent. (Item 15) 15. The pharmaceutical composition according to item 14, wherein the pH adjusting agent is coated with one or more layers of the dry pharmaceutical. (Item 16) 16. The pharmaceutical composition according to any one of items 3 to 15, wherein the first liquid comprises a pH optimizer. (Item 17) 17. The pharmaceutical composition of claim 16, wherein the pH optimizing agent is an acid. (Item 18) 18. The pharmaceutical composition according to item 17, wherein the acid is HCl, phosphoric acid or sulfuric acid. (Item 19) 19. The pharmaceutical composition according to any one of items 1 to 18, wherein the dry pharmaceutical is epinephrine. (Item 20) 17. The pharmaceutical composition according to item 16, wherein the pH optimizing agent is a base. (Item 21) 21. The pharmaceutical composition according to item 20, wherein the base is sodium hydroxide or potassium hydroxide. (Item 22) 22. The pharmaceutical composition according to any one of items 1 to 21, wherein the dry medicament is soluble at a pH of about 7.0 to 13.0. (Item 23) 23. The pharmaceutical composition according to any one of items 1 to 22, wherein the pH adjuster is an acid. (Item 24) 23. The pharmaceutical composition according to any one of items 1 to 22, wherein the pH adjuster is a base. (Item 25) 23. The pharmaceutical composition according to any one of items 1 to 22, wherein the one or more pH adjusting agents are selected from the group consisting of sodium and potassium buffering agents. (Item 26) 26. A method for preparing a medical solution, comprising mixing the pharmaceutical composition according to any one of items 1 to 25 with a first liquid. (Item 27) 27. The method of claim 26, wherein the first liquid is sterile. (Item 28) 27. The method of claim 26, wherein the first liquid comprises a solvent. (Item 29) 29. The method of claim 28, wherein the first liquid comprises water. (Item 30) 27. The method of claim 26, wherein the pH adjuster is sodium citrate, sodium acetate, potassium citrate, or potassium acetate. (Item 31) 27. The method of claim 26, wherein the first liquid comprises water and an acid. (Item 32) 27. The method of claim 26, wherein the first liquid comprises water and a base. (Item 33) 33. The method of any one of items 26 to 32, wherein the pharmaceutical composition is disposed in a first chamber of a medical device. (Item 34) 34. The method of any one of items 26 to 33, wherein the first liquid is disposed in a second chamber of the medical device. (Item 35) 35. The method of any one of items 33 to 34, wherein the medical device is an automatic injector or a syringe. (Item 36) 27. The method of claim 26, wherein the dry pharmaceutical forms a readily solubilized salt when mixed with the first liquid. (Item 37) 37. The pharmaceutical composition or method according to any one of items 1 to 36, wherein the dry medicament is epinephrine. (Item 38) 37. The pharmaceutical composition or method according to any one of items 1 to 36, wherein the dry medicament is epinephrine in free base form. (Item 39) 37. The pharmaceutical composition or method according to any one of items 1 to 36, wherein the dry pharmaceutical is epinephrine and the pH adjuster is citrate. (Item 40) 37. The pharmaceutical composition or method according to any one of items 1 to 36, wherein the dry medicament is 5 to 10% by weight and the pH adjuster is 90 to 95% by weight. (Item 41) 37. The pharmaceutical composition or method according to any one of items 1 to 36, wherein the dry medicament is glucagon. (Item 42) 37. The pharmaceutical composition or method according to any one of items 1 to 36, wherein the dry medicament is sumatriptan. (Item 43) 37. The pharmaceutical composition or method according to any one of items 3 to 36, wherein the first liquid comprises HCl. (Item 44) 37. The pharmaceutical composition or method according to any one of items 3 to 36, wherein the first liquid comprises HCl at a pH of 0.5 to 2.0. (Item 45) 37. The pharmaceutical composition or method according to any one of items 1 to 36, wherein the composition is an amorphous solid. (Item 46) 37. The pharmaceutical composition or method according to any one of items 1 to 36, wherein the composition is a porous matrix. [Brief explanation of the drawings]

[0015] [Figure 1] FIG. 1 illustrates a non-limiting method for a single-stage mixing and injection process.

[0016] [Figure 2] FIG. 2 illustrates a non-limiting embodiment of an injection system using the methods described herein.

[0017] [Figure 3] FIG. 3 shows Table 1 of non-limiting exemplary acids in the first liquid.

[0018] [Figure 4] FIG. 4 shows Table 2 of non-limiting exemplary pH adjusters.

[0019] [Figure 5] FIG. 5 shows Table 3 of non-limiting exemplary dry pharmaceutical and solubility-improved salt forms after mixing with a first liquid.

[0020] [Figure 6] 6 shows Table 4 of non-limiting exemplary reactions of dry pharmaceuticals with a first liquid and a pH adjuster. Specifically, the pharmaceutical forms a salt with an acid, its conjugate base, a base, or its conjugate acid to increase solubility, and the resulting exchange salt and weak acid form a solution for administration (e.g., injection). In certain embodiments, an excess of acid or conjugate salt can be added to adjust the pH of the final solution.

[0021] [Figure 7] FIG. 7 shows non-limiting exemplary reaction types 1 and 5, along with the molar ratios of each compound.

[0022] [Figure 8] FIG. 8 shows additional non-limiting exemplary reaction types 1 and 5.

[0023] [Figure 9] FIG. 9 shows non-limiting exemplary coatings of a pH adjuster with a dry pharmaceutical, where one or more particles of the dry pharmaceutical are present on particles of the pH adjuster (A), or the pH adjuster is coated with one or more layers of the dry pharmaceutical (B).

[0024] [Figure 10] FIG. 10 depicts non-limiting embodiments of mixtures comprising a dry pharmaceutical agent and a dry pH adjuster, where the particle size of the pharmaceutical agent is smaller (A) or larger (B) relative to the pH adjuster. DETAILED DESCRIPTION OF THE INVENTION

[0025] Provided herein are pharmaceutical compositions and kits comprising the therapeutic agents. Further provided herein are methods of treating or preventing a disease or condition using the pharmaceutical compositions and kits as described herein.

[0026] In some embodiments, aspects of the invention relate to stabilizing a therapeutic agent and making it less susceptible to temperature-induced degradation by preparing a dry pharmaceutical composition (e.g., a dry salt form) of the therapeutic agent that can be easily reconstituted for delivery to a patient (e.g., in the context of an autoinjector).

[0027] In some aspects, the present disclosure provides pharmaceutical compositions useful for storing medicaments in solid form, thereby preventing their degradation. The present disclosure further provides methods for preparing medical solutions from pharmaceutical compositions as described herein. In some embodiments, single-stage mixing is performed prior to injection, as illustrated in the scheme of FIG. 1. In some embodiments, when the pharmaceutical composition and the first liquid are mixed, the dry medicament dissolves faster than (e.g., before) one or more pH adjusters. In some embodiments, an injection system (e.g., as illustrated in FIG. 2 or any other suitable injector / autoinjector) is used in which the dry medicament composition is separated from the liquid components until they are mixed prior to injection. Tables 1-3 (FIGS. 3-5) provide non-limiting examples of acids (e.g., which may be provided in liquid form), pH adjusters (e.g., which may be provided in solid form), and medicaments (e.g., which may be provided in solid form) that can be used. Tables 4 and 5 (e.g., Figures 6-8) provide non-limiting examples of different types of reactions that may occur with the reagents of Tables 1-3 or other suitable reagents. In some embodiments, the pH adjuster acts to adjust the pH value of the mixture from a first pH preferred for dissolving the dry pharmaceutical to a second pH suitable for infusion into a subject.

[0028] In some embodiments, the dry medicament is generally not very soluble in water. In certain embodiments, the dry medicament is epinephrine. In certain embodiments, the dry medicament is epinephrine in free base form. In certain embodiments, the dry medicament is glucagon. In certain embodiments, the dry medicament is sumatriptan.

[0029] In certain embodiments, the dry pharmaceutical is not associated with one or more pH adjusting agents. In certain embodiments, the dry pharmaceutical and the one or more pH adjusting agents are different particles. In certain embodiments, the dry pharmaceutical is a smaller particle than the one or more pH adjusting agents. In certain embodiments, the dry pharmaceutical particles have a size greater than 1 nm. In certain embodiments, the dry pharmaceutical particles have a size greater than 5 nm. In certain embodiments, the dry pharmaceutical particles have a size greater than 10 nm. In certain embodiments, the dry pharmaceutical particles have a size greater than 50 nm. In certain embodiments, the dry pharmaceutical particles have a size greater than 100 nm. In certain embodiments, the dry pharmaceutical particles have a size greater than 500 nm. In certain embodiments, the dry pharmaceutical particles have a size greater than 1 μm. In certain embodiments, the dry pharmaceutical particles have a size greater than 5 μm. In certain embodiments, the dry pharmaceutical particles have a size greater than 10 μm. In some embodiments, the dry pharmaceutical particles have a size of about 20 μm to about 40 μm (e.g., about 20, 22.5, 25, 27.5, 30, 32.5, 35, or about 40 μm). In certain embodiments, the dry pharmaceutical particles have a size greater than 50 μm. In certain embodiments, the dry pharmaceutical particles have a size greater than 100 μm. In certain embodiments, the dry pharmaceutical particles have a size greater than 500 μm. In certain embodiments, one or more pH adjuster particles have a size greater than 1 nm. In certain embodiments, one or more pH adjuster particles have a size greater than 5 nm. In certain embodiments, one or more pH adjuster particles have a size greater than 10 nm. In certain embodiments, one or more pH adjuster particles have a size greater than 50 nm. In some embodiments, the one or more pH adjuster particles have a size of about 40 μm to about 60 μm (e.g., about 40, 45, 47.5, 50, 52.5, 55, 57.5, or about 60 μm). In certain embodiments, the one or more pH adjuster particles have a size greater than 100 nm.In certain embodiments, one or more pH adjuster particles have a size greater than 500 nm. In certain embodiments, one or more pH adjuster particles have a size greater than 1 μm. In certain embodiments, one or more pH adjuster particles have a size greater than 5 μm. In certain embodiments, one or more pH adjuster particles have a size greater than 10 μm. In certain embodiments, one or more pH adjuster particles have a size greater than 50 μm. In certain embodiments, one or more pH adjuster particles have a size greater than 100 μm. In certain embodiments, one or more pH adjuster particles have a size greater than 500 μm.

[0030] As used herein, particle size numerical values ​​refer to particle diameters as measured using known techniques (e.g., laser diffraction) and equipment (e.g., size range devices provided by Malvern). In some embodiments, the size of a particle is representative (e.g., mean, median, or average) of a population of particles (e.g., a dry composition). In some embodiments, the dry composition comprises an amorphous solid. In some embodiments, the dry composition comprises a crystalline solid. In some embodiments, the dry composition comprises a mixture of an amorphous solid and a crystalline solid. In some embodiments, the dry composition is a solid cake. In some embodiments, the dry composition is a porous matrix.

[0031] In certain embodiments, the dry medicament is a particle that dissolves before the one or more pH adjusters. In certain embodiments, the dry medicament particles dissolve faster than the one or more pH adjuster particles. In certain embodiments, the dry medicament is a particle that is larger than the one or more pH adjusters. In certain embodiments, the dry medicament is a particle of similar size to the one or more pH adjusters. As will be appreciated, different formulations (e.g., coatings, casings, etc.) of the dry medicament and the pH adjuster can alter the inherent solubility of these substances so that different dissolution rates are achieved.

[0032] In certain embodiments, the pH adjuster is coated with one or more layers of a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutically acceptable carrier is solid. Pharmaceutically acceptable carriers include any diluent, dispersant, suspending aid, surfactant, isotonicity agent, thickener or emulsifier, preservative, solid binder, lubricant, etc., suitable for a particular desired dosage form. General considerations in the formulation and / or manufacture of pharmaceutical compositions can be found, for example, in Remington's Pharmaceutical Sciences, 16th Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) and Remington: The Science and Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005).

[0033] In certain embodiments, the pH adjusting agent is coated with one or more layers of a pharmaceutically acceptable polymer. In certain embodiments, the pH adjusting agent is released after the dry medicament dissolves after mixing with the first liquid.

[0034] In certain embodiments, the dry medicament is associated with a pH adjusting agent (e.g., FIG. 9A). In certain embodiments, the pH adjusting agent is coated with one or more layers of the dry medicament (e.g., FIG. 9B). In certain embodiments, sodium citrate is coated with one or more layers of epinephrine.

[0035] In some embodiments, the different dissolution rates of the dry medicament and the pH adjuster are achieved by different particle sizes. In some embodiments, the particle size of the dry medicament is smaller relative to the particle size of the pH adjuster, such that the smaller medicament particles dissolve first and / or more quickly (e.g., FIG. 10A). In some embodiments, the particle size of the dry medicament is larger relative to the particle size of the pH adjuster (e.g., FIG. 10B). For example, in certain embodiments, the different dissolution rates of the dry medicament and the pH adjuster can be achieved by including a sustained-release coating on the pH adjuster. The characteristics of a particular sustained-release coating may be such that a smaller particle size provides a preferred dissolution rate of the pH adjuster.

[0036] As used herein, pH optimizer refers to a drug that has the ability to optimize the pH of solution.In certain embodiments, pH optimizer facilitates the dissolution of dry pharmaceuticals.In certain embodiments, pH optimizer is an acid as generally described herein.In certain embodiments, pH optimizer is a base as generally described herein.In certain embodiments, pH optimizer is a buffering agent.

[0037] As used herein, a pH adjusting agent is an agent that can change the pH value of a solution. In certain embodiments, the pH adjusting agent adjusts the pH of the solution to a physiologically acceptable pH suitable for administration. In certain embodiments, the pH adjusting agent is an acid, as generally described herein. In certain embodiments, the pH adjusting agent is a base, as generally described herein. In certain embodiments, the pH adjusting agent is a buffer, as generally described herein. In certain embodiments, the pH adjusting agent is a salt.

[0038] As generally defined herein, acids are those that dissociate in aqueous solution to form H +In certain embodiments, the acid is an organic acid. In certain embodiments, the acid is an inorganic acid. Examples of acids include, but are not limited to, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptan-1,2-ol, methylparaben ... Acids include carboxylic acid, ...In some embodiments, the acid is hydrochloric acid; sulfuric acid; phosphoric acid; maleic acid; 1-hydroxy-2-naphthoic acid; 2,2-dichloroacetic acid; 2-hydroxyethanesulfonic acid; 2-oxoglutaric acid; 4-acetamidobenzoic acid; 4-aminosalicylic acid; acetic acid; adipic acid; ascorbic acid (L); aspartic acid (L); benzenesulfonic acid; benzoic acid; camphoric acid (+); camphor-10-sulfonic acid (+); capric acid (decanoic acid); caproic acid (hexanoic acid); caprylic acid (octanoic acid); carbonic acid; cinnamic acid; citric acid; cyclamic acid; dodecylsulfuric acid; ethane-1,2-disulfonic acid; ethanesulfonic acid; formic acid; fumaric acid; galactaric acid; gentisic acid; Glucoheptonic acid (D); gluconic acid (D); glucuronic acid (D); glutamic acid; glutaric acid; glycerophosphoric acid; glycolic acid; hippuric acid; hydrobromic acid; hydrochloric acid; isobutyric acid; lactic acid (DL); lactobionic acid; lauric acid; maleic acid; malic acid (-L); malonic acid; mandelic acid (DL); methanesulfonic acid; naphthalene-1,5-disulfonic acid; naphthalene-2-sulfonic acid; nicotinic acid; nitric acid; oleic acid; oxalic acid; palmitic acid; pamoic acid; phosphoric acid; propionic acid; pyroglutamic acid (-L); salicylic acid; sebacic acid; stearic acid; succinic acid; sulfuric acid; tartaric acid (+L); thiocyanic acid; toluenesulfonic acid (p) or undecylenic acid. In some embodiments, the acid is sulfuric acid, hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, perchloric acid, formic acid, acetic acid, propionic acid, oxalic acid, maleic acid, citric acid, succinic acid, malonic acid, tartaric acid, or a combination thereof. In certain embodiments, the acid is hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, tartaric acid, malic acid, malonic acid, maleic acid, fumaric acid, succinic acid, or formic acid (e.g., Figure 5).

[0039] As generally defined herein, a base is one that dissociates in aqueous solution to form OH. -In certain embodiments, the base is an organic base. In certain embodiments, the base is an inorganic base. In certain embodiments, the base is an alkaline base. Examples of bases include, but are not limited to, sodium citrate, sodium acetate, sodium hydroxide, potassium hydroxide, lithium hydroxide, ammonium hydroxide, calcium hydroxide, magnesium hydroxide, iron hydroxide, zinc hydroxide, copper hydroxide, manganese hydroxide, aluminum hydroxide, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, tromethamine, N-methylglucamine, or a combination thereof. In some embodiments, the base is sodium hydroxide or potassium hydroxide.

[0040] As used herein, the term "buffer" refers to a buffering agent or a buffer solution containing one or more buffering agents. As generally defined herein, a buffering agent is a weak acid or base used to maintain the pH of a solution near a selected value after the addition of another acid or base. The function of a buffering agent is to prevent a sudden change in pH when an acid or base is added to the solution. Exemplary buffering agents include, but are not limited to, citrate buffer, acetate buffer, phosphate buffer, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixture, dipotassium phosphate, potassium dihydrogen phosphate, potassium phosphate mixture, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, sodium dihydrogen phosphate, sodium phosphate mixture, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and mixtures thereof. In certain embodiments, the buffering agent is a sodium salt, a calcium salt, a potassium salt, or an ammonium salt. In certain embodiments, the buffering agent is citrate, acetate, phosphate, sulfate, nitrate, tartrate, succinate, malate, or maleate (e.g., Figure 4). In certain embodiments, the buffering agent is sodium citrate, sodium acetate, potassium hydroxide, potassium citrate, potassium acetate, sodium succinate, or potassium succinate.

[0041] As used herein, a first liquid may be a solvent or a solution. In some embodiments, the first liquid is a single solvent. In some embodiments, the first liquid is a solution comprising a pH optimizing agent and a single solvent. In some embodiments, the first liquid comprises water. In some embodiments, the first liquid comprises water and a pH optimizing agent. In some embodiments, the pH optimizing agent is an acid, as generally defined herein. In some embodiments, the pH optimizing agent is HCl. In some embodiments, the first liquid is an aqueous solution comprising HCl. In some embodiments, the pH optimizing agent is a base, as generally defined herein. In some embodiments, the pH optimizing agent is an alkaline base.

[0042] In some embodiments, the pH of the first liquid is about 0.1 to about 6.9. In some embodiments, the pH of the first liquid is about 0.5 to about 5.0. In some embodiments, the pH of the first liquid is about 1.0 to about 5.0. In some embodiments, the pH of the first liquid is about 2.0 to about 5.0. In one embodiment, the pH of the first liquid is about 0.1 to about 6.0. In one embodiment, the pH of the first liquid is about 0.1 to about 5.0. In one embodiment, the pH of the first liquid is about 0.1 to about 4.0. In one embodiment, the pH of the first liquid is about 0.1 to about 3.0. In one embodiment, the pH of the first liquid is about 0.1 to about 2.0. In one embodiment, the pH of the first liquid is about 0.1 to about 1.0. In one embodiment, the pH of the first liquid is about 0.01 to about 2.2, and the dry pharmaceutical is epinephrine. In some embodiments, the pH of the first liquid is about 0.25 to about 0.50. In some embodiments, the pH of the first liquid is about 0.50 to about 0.75. In some embodiments, the pH of the first liquid is about 0.75 to about 1.0. In some embodiments, the pH of the first liquid is about 1.0 to about 1.25. In one embodiment, the pH of the first liquid is 1.25. In some embodiments, the pH of the first liquid is about 1.25 to about 1.5. In some embodiments, the pH of the first liquid is about 1.5 to about 1.75. In some embodiments, the pH of the first liquid is about 1.75 to about 2.0. In some embodiments, the pH of the first liquid is about 2.0 to about 2.25. In some embodiments, the pH of the first liquid is about 2.25 to about 2.5. In some embodiments, the pH of the first liquid is about 2.5 to about 2.75. In some embodiments, the pH of the first liquid is about 2.75 to about 3.0.

[0043] In some embodiments, the pH of the first liquid is about 7.0 to about 13.5. In some embodiments, the pH of the first liquid is about 8.0 to about 13.5. In some embodiments, the pH of the first liquid is about 9.0 to about 13.5. In some embodiments, the pH of the first liquid is about 9.5 to about 13.5. In some embodiments, the pH of the first liquid is about 9.5 to about 13.5, and the dry pharmaceutical is glucagon.

[0044] In some embodiments, when the pharmaceutical composition and the first liquid are mixed, the dry medicament dissolves faster than the one or more pH adjusters. In some embodiments, the pH adjuster acts to adjust the pH value of the mixture from a preferred pH for dissolving the dry medicament to a pH suitable for infusion into a subject (e.g., as illustrated by the reagents and reactions in Figures 3-8). In certain embodiments, the pH of the final solution is a physiologically acceptable pH. In some embodiments, the pH of the final solution is about 2.2 to about 5.0, and the dry medicament is epinephrine. In some embodiments, the pH of the final solution is about 2.2 to about 5.0, and the dry medicament is epinephrine free base form. In some embodiments, the pH of the final solution is about 2.2 to about 5.0, and the dry medicament is epinephrine salt form. In some embodiments, the pH of the final solution is about 2.2 to about 5.0, and the dry medicament is epinephrine hydrochloride form. In some embodiments, the pH of the final solution is about 2.2 to about 5.0, and the dry pharmaceutical is epinephrine bitartrate form. In some embodiments, the pH of the final solution is about 4.2 to about 5.3, and the dry pharmaceutical is sumatriptan. In some embodiments, the pH of the final solution is about 0.1 to about 3.0, and the dry pharmaceutical is glucagon.

[0045] Dry pharmaceutical compositions can be prepared by any suitable method, such as those used in pharmaceutical formulations. For example, the drug can be chemically derivatized, lyophilized (freeze-dried), and / or spray-dried, and / or any other technique that renders the drug and / or medicament in a dry form can be used. However, in some embodiments, it is important that the dried drug be easily and quickly soluble so that the dry composition can be used in an automatic injector that also contains a liquid component that can mix with the dry drug and solubilize it upon actuation of the automatic injector (e.g., just before or at the time of injection).

[0046] There are many common drug formulations that contain some form of epinephrine, including those used to treat cardiac arrest and anaphylaxis. Due to the insolubility of epinephrine free base, the final dosage form of epinephrine used in healthcare is generally formulated using an acid to form the hydrochloride, bitartrate, or borate salts.

[0047] In some embodiments, a pharmaceutical composition comprising L-epinephrine free base is disposed in a chamber of a medical device (e.g., an autoinjector). A first liquid comprising a pH optimizer (e.g., an acid such as HCl) is disposed in another chamber. In one embodiment, the HCl solution is 1 M or higher. In some embodiments, the HCl solution is 0.1 M or higher. In some embodiments, the HCl solution is 0.01 M or higher. In some embodiments, the HCl solution is 0.001 M or higher. In some embodiments, the HCl solution is 0.0001 M or higher. In some embodiments, the HCl solution is 0.00001 M or higher. In some embodiments, the HCl solution is 0.000001 M or higher. In some embodiments, the HCl solution is 0.000001 M or higher.

[0048] In some embodiments, the volume of the first liquid (e.g., in the power injector) is about 100 μL to about 200 μL (e.g., about 100, 125, 150, 175, or about 200 μL). In some embodiments, the volume of the first liquid (e.g., in the power injector) is about 200 μL to about 300 μL (e.g., about 200, 225, 250, 275, or about 300 μL). In some embodiments, the volume of the first liquid (e.g., in the power injector) is about 300 μL to about 400 μL (e.g., about 300, 325, 350, 375, or about 400 μL). In some embodiments, the volume of the first liquid (e.g., in the power injector) is about 400 μL to about 500 μL (e.g., about 400, 425, 450, 475, or about 500 μL). In some embodiments, the volume of the first liquid (e.g., in the power injector) is about 500 μL to about 600 μL (e.g., about 500, 525, 550, 575, or about 600 μL). In some embodiments, the volume of the first liquid (e.g., in the power injector) is about 600 μL to about 700 μL (e.g., about 600, 625, 650, 675, or about 700 μL). In some embodiments, the volume of the first liquid (e.g., in the power injector) is about 700 μL to about 800 μL (e.g., about 700, 725, 750, 775, or about 800 μL). In some embodiments, the volume of the first liquid (e.g., in the power injector) is about 800 μL to about 1000 μL (e.g., about 800, 850, 900, 950, or about 1000 μL). In some embodiments, the volume of the first liquid (e.g., in the power injector) is about 1 mL to about 1.5 mL (e.g., about 1, 1.1, 1.2, 1.3, 1.4, or about 1.5 mL). In some embodiments, the liquid is of a volume greater than 1.5 mL.

[0049] In one embodiment, additional components such as metabisulfite, sodium chloride and other materials may also be included in the first liquid to dissolve therapeutic agents such as epinephrine.

[0050] In one embodiment, epinephrine free base is dissolved in a first liquid containing a pH optimizer such that the pH of the dissolved material is less than 6, less than 5, less than 4, less than 3, less than 2, or between 2 and 5. In one embodiment, the dissolved epinephrine solution is then adjusted with a pH adjuster to a final pH that is physiologically acceptable for administration.

[0051] In certain embodiments, the first solution is added to the dry composition comprising the dry pharmaceutical agent and the dry pH adjusting agent.In some embodiments, the first solution comprises a pH optimizing agent.In certain embodiments, the pH optimizing agent is an acid.In certain embodiments, the pH optimizing agent is a base.In certain embodiments, the pH optimizing agent is a buffering agent.

[0052] In certain embodiments, the dry pharmaceutical dissolves in the first solution faster than the dry pH adjuster. However, as the pH adjuster dissolves, it adjusts the pH of the resulting solution, for example, to a more physiologically acceptable pH range than the pH of the first solution. In some embodiments, the dry pH adjuster is an acid. In some embodiments, the dry pH adjuster is a base. In some embodiments, the dry pH adjuster is a buffer. In certain embodiments, the buffer comprises a salt of a weak acid or a salt of a weak base, such as sodium acetate (e.g., in dry powder form). In some embodiments, the buffer may comprise a mixture of a weak acid and its conjugate base or a weak base and its conjugate acid (e.g., in dry powder form). In some embodiments, the buffer may comprise a mixture of citric acid and its conjugate base (e.g., in dry powder form). In some embodiments, the buffer may comprise a mixture of acetic acid and its conjugate base (e.g., in dry powder form). In some embodiments, the buffer may comprise a mixture of tartaric acid and its conjugate base (e.g., in dry powder form). In some embodiments, a buffering agent (e.g., in dry powder form) for adjusting the pH of the dissolved pharmaceutical solution is already mixed with the dry pharmaceutical as described herein. However, in some embodiments, the buffering agent (e.g., in dry powder form) is included inside a reservoir for receiving the dissolved solution. In some embodiments, the buffering agent may be useful for increasing the pH of the dissolved solution to a pH above 2 if the pH upon dissolution drops to a pH below 2. In some embodiments, the pH-adjusting dry pharmaceutical is a base. In some embodiments, the pH-adjusting dry pharmaceutical is sodium hydroxide. In some embodiments, adjusting the pH of the solution with the pH-adjusting agent makes the resulting solution suitable for injection. It should be understood that in some embodiments, one feature is that the pharmaceutical is provided in an acid or base to facilitate dissolution of the pharmaceutical, and the buffering agent adjusts the mixture to a pH suitable for injection.

[0053] In certain embodiments, one powdered form of epinephrine is, for example, -(-) epinephrine free base. -(-) epinephrine (epi) has low solubility in water. However, adding a pH optimizer to the aqueous solution can increase its solubility. In certain embodiments, adding an acid, such as hydrochloric acid (HCl), makes the environment more acidic, thereby increasing the solubility of epinephrine.

[0054] The addition of acid promotes more rapid dissolution of epinephrine. Improving dissolution rate is important when epinephrine needs to be dissolved more quickly before injection, for example, in an autoinjector or prefilled syringe. In certain embodiments, rapid dissolution of epinephrine is achieved by lowering the pH to less than about 2.2. This can be adjusted back to a pH value of about 2.2 to about 5 before injection. In one embodiment, the pH value at which epinephrine dissolves is about 2.2 or less. In one embodiment, the pH value of the injection solution containing epinephrine is about 2.2 or less. In one embodiment, the pH value of the injection solution containing epinephrine is about 5.0 or greater.

[0055] Several approaches can be used to adjust the pH value from below about 2.2 to a range of about 2.2 to about 5. In some embodiments, one or more pH adjusting agents (e.g., in dry form) are present in the dry composition containing the pharmaceutical to form a buffer system. In certain embodiments, the pH adjusting agent is a buffering agent. In certain embodiments, the pH adjusting agent is a buffering agent. In certain embodiments, the buffering agent is a sodium or potassium buffering agent. In certain embodiments, the buffering agent is sodium citrate or sodium acetate. In certain embodiments, the buffer system comprises trisodium citrate and citric acid.

[0056] In some embodiments, the methods provided herein enable rapid dissolution of a medication (e.g., epinephrine) within a medical device (e.g., an autoinjector or pre-filled syringe) by using a first liquid (e.g., an acidic solution) to dissolve the epinephrine, followed by pH adjustment due to the slower dissolution of a pH adjusting agent (e.g., a buffering agent) to reach a final pH range for injection of about 2.2 to about 5.

[0057] In some embodiments, the following reaction types are involved: [ka]

[0058] As shown in Eqs. 1-3, sodium citrate and epinephrine powder react with hydrochloric acid to produce epinephrine hydrochloride and sodium chloride in citric acid solution. Citric acid is a triprotic weak acid with an acid dissociation constant (pKa) of three. This dissociation reaction is shown in Eqs. 4-6. [ka]

[0059] The pKa value of citric acid is within the pH of the target infusion solution. Systems containing citric acid have better buffering capacity and resistance to pH drift. The combined and balanced reaction (Equation 3) results in a solution with the target pH and epinephrine concentration for infusion. The pH and sodium chloride concentration of the solution can be adjusted by varying the relative ratios of HCl:sodium citrate and / or sodium citrate:epinephrine. In certain embodiments, the molar ratio of HCl:sodium citrate is about 100:1 to about 1:100. In certain embodiments, the molar ratio of HCl:sodium citrate is about 80:1 to about 1:100. In certain embodiments, the molar ratio of HCl:sodium citrate is about 60:1 to about 1:100. In certain embodiments, the molar ratio of HCl:sodium citrate is about 40:1 to about 1:100. In certain embodiments, the molar ratio of HCl:sodium citrate is about 20:1 to about 1:100. In certain embodiments, the molar ratio of HCl:sodium citrate is about 10:1 to about 1:100. In certain embodiments, the molar ratio of HCl:sodium citrate is about 5:1 to about 1:100. In certain embodiments, the molar ratio of HCl:sodium citrate is about 10:1 to about 1:100. In certain embodiments, the molar ratio of HCl:sodium citrate is about 100:1 to about 1:80. In certain embodiments, the molar ratio of HCl:sodium citrate is about 100:1 to about 1:60. In certain embodiments, the molar ratio of HCl:sodium citrate is about 100:1 to about 1:40. In certain embodiments, the molar ratio of HCl:sodium citrate is about 100:1 to about 1:20. In certain embodiments, the molar ratio of HCl:sodium citrate is about 100:1 to about 1:10. In certain embodiments, the molar ratio of HCl:sodium citrate is about 100:1 to about 1:5. In certain embodiments, the molar ratio of HCl:sodium citrate is about 100:1 to about 1:1. In certain embodiments, the molar ratio of HCl:sodium citrate is about 50:1 to about 1:50. In certain embodiments, the molar ratio of HCl:sodium citrate is about 20:1 to about 1:20.In certain embodiments, the molar ratio of HCl:sodium citrate is from about 10:1 to about 1:10. In certain embodiments, the molar ratio of HCl:sodium citrate is from about 5:1 to about 1:5.

[0060] In some embodiments, both epinephrine and sodium citrate are mixed with a first liquid containing an acid (e.g., HCl). The buffering effect can be achieved by the reversible reaction between citric acid and its conjugate base, sodium citrate (eq. 4). In certain embodiments, trisodium citrate is added to increase the citrate ion in excess HCl to drive the solution equilibrium to the left, thereby increasing the pH of the solution (e.g., to a range of about 2.2 to about 5.0). In some embodiments, both epinephrine and sodium acetate are mixed with a first liquid containing an acid (e.g., HCl). In some embodiments, both epinephrine and sodium bitartrate are mixed with a first liquid containing an acid (e.g., HCl).

[0061] In certain embodiments, a medical device is provided herein that stores a dry medication in a first chamber and a first liquid in a second chamber. The dry powder medication can be rapidly dissolved in the first liquid, followed by pH adjustment to a pH suitable for injection due to the slower dissolution of a pH adjusting agent (e.g., provided mixed with the medication in a dry composition). In some embodiments, the benefits of the thermal stability of the powder medication combined with the ability to rapidly dissolve the powder medication in a liquid dose immediately prior to delivery provide patients with medication with much less storage requirements and a longer shelf life. In certain embodiments, the medical device is an autoinjector. In certain embodiments, a powdered form of epinephrine is placed in the first chamber of the autoinjector, and an aqueous solution containing an acid is placed in the second chamber of the autoinjector. In some embodiments, the powdered form of epinephrine is mixed with a powdered form of a pH adjusting agent (e.g., a dry form of a buffering agent).

[0062] In some embodiments, a dry composition comprising a dry pharmaceutical (e.g., epinephrine, glucagon, or other pharmaceutical) and a dry pH adjuster (e.g., citrate, acetate, or other pH adjuster) is provided (e.g., in an autoinjector) in a weight range of about 25 mg to about 50 mg (e.g., about 25, 27.5, 30, 32.5, 35, 37.5, 40, 42.5, 45, 47.5, or about 50 mg). In some embodiments, a dry composition comprising a dry pharmaceutical (e.g., epinephrine, glucagon, or other pharmaceutical) and a dry pH adjuster (e.g., citrate, acetate, or other pH adjuster) is provided (e.g., in an autoinjector) in a weight range of about 15 to about 25 mg (e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or about 25 mg). In some embodiments, a dry composition comprising a dry pharmaceutical (e.g., epinephrine, glucagon, or other pharmaceutical) and a dry pH adjuster (e.g., citrate, acetate, or other pH adjuster) is provided (e.g., in an autoinjector) in a weight range of about 5 to about 15 mg (e.g., about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or about 15 mg). In some embodiments, a dry composition comprising a dry pharmaceutical (e.g., epinephrine, glucagon, or other pharmaceutical) and a dry pH adjuster (e.g., citrate, acetate, or other pH adjuster) is provided (e.g., in an autoinjector) in a weight range of about 3 to about 5 mg (e.g., about 3, 3.25, 3.5, 3.75, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.75, or about 5 mg). In some embodiments, a dry composition comprising a dry pharmaceutical (e.g., epinephrine, glucagon, or other pharmaceutical) and a dry pH adjuster (e.g., citrate, acetate, or other pH adjuster) is provided (e.g., in an autoinjector) in a weight range of about 1 mg to about 3 mg (e.g., about 1, 1.25, 1.5, 1.75, 2, 2.1, 2.15, 2.17, 2.2, 2.3, 2.4, 2.5, 2.75, or about 3 mg). In some embodiments, a dry composition comprising a dry pharmaceutical (e.g., epinephrine, glucagon, or other pharmaceutical) and a dry pH adjuster (e.g., citrate, acetate, or other pH adjuster) is provided (e.g., in an autoinjector) in a weight range of about 0.1 mg to about 1 mg (e.g., about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or about 1 mg).

[0063] In certain embodiments, medical devices comprising a dry composition are provided herein. In some embodiments, the dry composition comprises a dry pharmaceutical. In some embodiments, the dry composition comprises a dry pharmaceutical (e.g., epinephrine, glucagon, or other pharmaceutical) and a dry pH adjusting agent (e.g., citrate, acetate, or other pH adjusting agent). In some embodiments, the dry composition comprises about 1% by weight of the dry pharmaceutical and about 99% by weight of the dry pH adjusting agent. In some embodiments, the dry composition comprises about 2% by weight of the dry pharmaceutical and about 98% by weight of the dry pH adjusting agent. In some embodiments, the dry composition comprises about 3% by weight of the dry pharmaceutical and about 97% by weight of the dry pH adjusting agent. In some embodiments, the dry composition comprises about 4% by weight of the dry pharmaceutical and about 96% by weight of the dry pH adjusting agent. In some embodiments, the dry composition comprises about 5% by weight of the dry pharmaceutical and about 95% by weight of the dry pH adjusting agent. In some embodiments, the dry composition comprises about 6% by weight of the dry pharmaceutical and about 94% by weight of the dry pH adjusting agent. In some embodiments, the dry composition comprises about 7% by weight of dry pharmaceutical agent and about 93% by weight of dry pH adjusting agent. In some embodiments, the dry composition comprises about 8% by weight of dry pharmaceutical agent and about 92% by weight of dry pH adjusting agent. In some embodiments, the dry composition comprises about 9% by weight of dry pharmaceutical agent and about 91% by weight of dry pH adjusting agent. In some embodiments, the dry composition comprises about 10% by weight of dry pharmaceutical agent and about 90% by weight of dry pH adjusting agent. In some embodiments, the dry composition comprises about 10% to about 15% by weight of dry pharmaceutical agent and about 85% to about 90% by weight of dry pH adjusting agent. For example, about 10%, 11%, 12%, 13%, 14%, or about 15% by weight of dry pharmaceutical agent and about 85%, 86%, 87%, 88%, 89%, or about 90% by weight of dry pH adjusting agent. In some embodiments, the dry composition comprises about 15% to about 20% by weight of dry pharmaceutical agent and about 80% to about 85% by weight of dry pH adjusting agent, e.g., about 15%, 16%, 17%, 18%, 19%, or about 20% by weight of dry pharmaceutical agent and about 80%, 81%, 82%, 83%, 84%, or about 85% by weight of dry pH adjusting agent.In some embodiments, the dry composition comprises about 20% to about 25% by weight of dry pharmaceutical agent and about 75% to about 80% by weight of dry pH adjusting agent. For example, about 20%, 21%, 22%, 23%, 24%, or about 25% by weight of dry pharmaceutical agent and about 75%, 76%, 77%, 78%, 79%, or about 80% by weight of dry pH adjusting agent. In some embodiments, the dry composition comprises about 25% to about 40% by weight of dry pharmaceutical agent and about 60% to about 75% by weight of dry pH adjusting agent. For example, about 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, or about 40% by weight of dry pharmaceutical agent and about 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, or about 80% by weight of dry pH adjusting agent. In some embodiments, the dry composition comprises about 40% to about 55% by weight of dry pharmaceutical agent and about 45% to about 60% by weight of dry pH adjusting agent. For example, about 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, or about 55% by weight of dry pharmaceutical agent and about 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, or about 60% by weight of dry pH adjusting agent. In some embodiments, the dry composition comprises about 55% to about 70% by weight of dry pharmaceutical agent and about 30% to about 45% by weight of dry pH adjusting agent. For example, about 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, or about 70% by weight of dry pharmaceutical agent and about 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, or about 45% by weight of dry pH adjusting agent. In some embodiments, the dry composition comprises about 70% to about 85% by weight of dry pharmaceutical agent and about 15% to about 30% by weight of dry pH adjusting agent. For example, about 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, or about 85% by weight of dry pharmaceutical agent and about 15%, 17.5%, 20%, 22.5%, 25%, 27.5%, or about 30% by weight of dry pH adjusting agent. In some embodiments, the dry composition comprises about 85% to about 99% by weight of dry pharmaceutical agent and about 1% to about 15% by weight of dry pH adjusting agent.For example, about 85%, 87.5%, 90%, 92.5%, 95%, 97.5% or about 99% by weight dry pharmaceutical agent and about 1%, 2.5%, 5%, 7.5%, 10%, 12.5%, or about 15% by weight dry pH adjuster.

[0064] In some embodiments, the dry composition comprises about 1% epinephrine and about 99% citrate by weight. In some embodiments, the dry composition comprises about 2% epinephrine and about 98% citrate by weight. In some embodiments, the dry composition comprises about 3% epinephrine and about 97% citrate by weight. In some embodiments, the dry composition comprises about 4% epinephrine and about 96% citrate by weight. In some embodiments, the dry composition comprises about 5% epinephrine and about 95% citrate by weight. In some embodiments, the dry composition comprises about 6% epinephrine and about 94% citrate by weight. In some embodiments, the dry composition comprises about 7% epinephrine and about 93% citrate by weight. In some embodiments, the dry composition comprises about 8% epinephrine and about 92% citrate by weight. In some embodiments, the dry composition comprises about 9% epinephrine and about 91% citrate by weight. In some embodiments, the dry composition comprises about 10% by weight epinephrine and about 90% by weight citrate. In some embodiments, the dry composition comprises about 10% to about 15% by weight epinephrine and about 85% to about 90% by weight citrate. For example, about 10%, 11%, 12%, 13%, 14%, or about 15% by weight epinephrine and about 85%, 86%, 87%, 88%, 89%, or about 90% by weight citrate. In some embodiments, the dry composition comprises about 15% to about 20% by weight epinephrine and about 80% to about 85% by weight citrate. For example, about 15%, 16%, 17%, 18%, 19%, or about 20% epinephrine by weight and about 80%, 81%, 82%, 83%, 84%, or about 85% citrate by weight. In some embodiments, the dry composition comprises about 20% to about 25% epinephrine by weight and about 75% to about 80% citrate by weight. For example, about 20%, 21%, 22%, 23%, 24%, or about 25% epinephrine by weight and about 75%, 76%, 77%, 78%, 79%, or about 80% citrate by weight.In some embodiments, the dry composition comprises about 25% to about 40% epinephrine by weight and about 60% to about 75% citrate by weight (e.g., about 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, or about 40% epinephrine by weight and about 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, or about 80% citrate by weight). In some embodiments, the dry composition comprises about 40% to about 55% epinephrine by weight and about 45% to about 60% citrate by weight. For example, about 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, or about 55% epinephrine by weight and about 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, or about 60% citrate by weight. In some embodiments, the dry composition comprises about 55% to about 70% epinephrine by weight and about 30% to about 45% citrate by weight. For example, about 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, or about 70% epinephrine by weight and about 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, or about 45% citrate by weight. In some embodiments, the dry composition comprises about 70% to about 85% epinephrine by weight and about 15% to about 30% citrate by weight (e.g., about 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, or about 85% epinephrine by weight and about 15%, 17.5%, 20%, 22.5%, 25%, 27.5%, or about 30% citrate by weight). In some embodiments, the dry composition comprises about 85% to about 99% epinephrine by weight and about 1% to about 15% citrate by weight. For example, about 85%, 87.5%, 90%, 92.5%, 95%, 97.5%, or about 99% epinephrine by weight and about 1%, 2.5%, 5%, 7.5%, 10%, 12.5%, or about 15% citrate by weight.

[0065] In some embodiments, the dry composition comprises about 1% glucagon and about 99% citrate by weight. In some embodiments, the dry composition comprises about 2% glucagon and about 98% citrate by weight. In some embodiments, the dry composition comprises about 3% glucagon and about 97% citrate by weight. In some embodiments, the dry composition comprises about 4% glucagon and about 96% citrate by weight. In some embodiments, the dry composition comprises about 5% glucagon and about 95% citrate by weight. In some embodiments, the dry composition comprises about 6% glucagon and about 94% citrate by weight. In some embodiments, the dry composition comprises about 7% glucagon and about 93% citrate by weight. In some embodiments, the dry composition comprises about 8% glucagon and about 92% citrate by weight. In some embodiments, the dry composition comprises about 9% glucagon and about 91% citrate by weight. In some embodiments, the dry composition comprises about 10% glucagon and about 90% citrate by weight. In some embodiments, the dry composition comprises about 10% to about 15% glucagon by weight and about 85% to about 90% citrate by weight (e.g., about 10%, 11%, 12%, 13%, 14%, or about 15% glucagon by weight and about 85%, 86%, 87%, 88%, 89%, or about 90% citrate by weight). In some embodiments, the dry composition comprises about 15% to about 20% glucagon by weight and about 80% to about 85% citrate by weight (e.g., about 15%, 16%, 17%, 18%, 19%, or about 20% glucagon by weight and about 80%, 81%, 82%, 83%, 84%, or about 85% citrate by weight). In some embodiments, the dry composition comprises about 20% to about 25% glucagon by weight and about 75% to about 80% citrate by weight (e.g., about 20%, 21%, 22%, 23%, 24%, or about 25% glucagon by weight and about 75%, 76%, 77%, 78%, 79%, or about 80% citrate by weight). In some embodiments, the dry composition comprises about 25% to about 40% glucagon by weight and about 60% to about 75% citrate by weight.For example, about 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, or about 40% glucagon by weight and about 60%, 62.5%, 65%, 67.5%, 70%, 72.5%, or about 80% citrate by weight. In some embodiments, the dry composition comprises about 40% to about 55% glucagon by weight and about 45% to about 60% citrate by weight. For example, about 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, or about 55% glucagon by weight and about 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, or about 60% citrate by weight. In some embodiments, the dry composition comprises about 55% to about 70% glucagon by weight and about 30% to about 45% citrate by weight (e.g., about 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, or about 70% glucagon by weight and about 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, or about 45% citrate by weight). In some embodiments, the dry composition comprises about 70% to about 85% glucagon by weight and about 15% to about 30% citrate by weight. For example, about 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, or about 85% glucagon by weight and about 15%, 17.5%, 20%, 22.5%, 25%, 27.5%, or about 30% citrate by weight. In some embodiments, the dry composition comprises about 85% to about 99% glucagon by weight and about 1% to about 15% citrate by weight. For example, about 85%, 87.5%, 90%, 92.5%, 95%, 97.5%, or about 99% glucagon by weight and about 1%, 2.5%, 5%, 7.5%, 10%, 12.5%, or about 15% citrate by weight.

[0066] It should be understood that a dry form of a medicament, acid, base, buffer or other compound described herein refers to one or more of a powder, solid form, crystalline form, pellet, particle or other dry form of the compound.

[0067] In some embodiments, the dry composition comprises dry epinephrine free base. In some embodiments, the dry drug composition comprises dry L-epinephrine free base. In some embodiments, the dry drug composition comprises a dry epinephrine salt. In some embodiments, the epinephrine salt is epinephrine maleate, malate, fumarate, acid tartrate, bitartrate, or sulfate. In some embodiments, the epinephrine salt is epinephrine hydrochloride. In some embodiments, the epinephrine salt is epinephrine bitartrate. In some embodiments, the epinephrine salt is epinephrine borate. In some embodiments, the epinephrine is L-epinephrine. In some embodiments, the dry drug composition further comprises a dry pH adjuster. In some embodiments, the dry drug composition further comprises a salt and / or an antioxidant. In some embodiments, the dry drug composition comprises sodium metabisulfite and / or mannitol.

[0068] In some embodiments, the dry composition is prepared by drying a solution (e.g., by vacuum drying, freeze-drying, lyophilization, or any suitable drying technique, as aspects of the invention are not limited in this regard). In some embodiments, the dry composition is placed inside the autoinjector as a dry powder. In some embodiments, the dry composition can have any suitable particle size that allows for efficient and rapid dissolution, solubilization, or reconstitution. In some embodiments, the particle size of the dry composition can be controlled by drying the drug solution within a confined volume. For example, in some embodiments, the drug solution is dried within a confined area of ​​the autoinjector (e.g., within one or more microfluidic channels of the autoinjector). As a result, the particle size of the dried drug composition can be on the order of the diameter of the microfluidic channel (e.g., about 1 micron to about 500 microns in diameter). However, in some embodiments, smaller or larger particle sizes can be used.

[0069] It should be understood that the composition may be dried to different degrees depending on the conditions used and the nature of the composition (e.g., the drug or other components of the composition). In some embodiments, the dried composition has less than 50% water by weight, less than 40% water by weight, less than 30% water by weight, less than 20% water by weight, less than 10% water by weight, less than 5% water by weight, less than 1% water by weight, less than 0.1% water by weight, less than 0.01% water by weight, or less.

[0070] In some embodiments, the pharmaceutical agent and pH adjusting agent are mixed in solution before drying to a powder form. In some embodiments, the pharmaceutical agent and pH adjusting agent are dried separately. In some embodiments, the dried pharmaceutical agent and the dried pH adjusting agent are independently processed to achieve a desired particle size ratio using known techniques (e.g., micronizing, milling, grinding, pulverizing).

[0071] In some embodiments, the components of the composition are weighed and measured so that the final concentration of the therapeutic agent or medicament (e.g., L-epinephrine) in the solution is 1 mg / mL. In one embodiment, the final concentration of the therapeutic agent or medicament (e.g., L-epinephrine) is 0.8 mg / mL to 1.2 mg / mL. In one embodiment, the final concentration of the therapeutic agent or medicament (e.g., L-epinephrine) is 0.7 mg / mL to 1.3 mg / mL. In some embodiments, the final concentration of the therapeutic agent or medicament (e.g., L-epinephrine) is less than 0.8 mg / mL, e.g., less than 0.7 mg / mL. In some embodiments, the final concentration of the therapeutic agent or medicament (e.g., L-epinephrine) is greater than 1.2 mg / mL, e.g., greater than 1.3 mg / mL.

[0072] In some embodiments, the concentration of one or more components (e.g., one or more acids, bases, buffers, salts, additives, therapeutic agents, medicaments, drugs, or other components described herein) is between 1 nM and 1 M, e.g., between 1 nM and 1 μM, 1 μM and 1 mM, 1 mM and 10 mM, 10 mM and 100 mM, 100 mM and 500 mM, 500 mM and 1 M, about 1 mM, about 5 mM, about 10 mM, about 50 mM, about 100 mM, about 500 mM, about 1 M, or a higher or lower range depending on the component and / or application (e.g., in the final solution after dissolution).

[0073] A non-limiting example of an injection system (e.g., a syringe / autoinjector device) is shown in FIG. 2. The injection system 20 includes a syringe 40 (e.g., for holding liquid components) and a mixer 22 (e.g., for holding a dry pharmaceutical composition). The syringe 40 includes a cylindrical tube 42 that defines a volume. The cylindrical tube 42 of the syringe 40 tapers toward an outlet port 48. The syringe 40 includes a plunger 50 with a depressible handle 52, a shaft 54, and a piston 56 for forcing the liquid components 26 out of the outlet port 48. The injector 30 may be separate from the mixer 22 but is shown as a needle 60 that is part of the mixer 22. The injector 30 may be a nozzle or tube for delivery of the combined pharmaceutical 28. The mixer 22 is illustrated with a housing 64 that defines an internal flow chamber 66 with an inlet 68 and an outlet 70. The mixer 22 is shown with a single channel, such as microchannel 124. In this embodiment, the microchannel 124 of the mixing device 22 is a serpentine channel that defines a fluid path between the inlet 68 and the outlet 70. Fluid can flow in and out of the inlet 68 as well as the outlet 70. The serpentine channel 124 has two functions: first, it allows for a compact channel structure by bending the fluid flow direction so that the channel can turn around, thereby allowing longer channels to more efficiently utilize smaller areas. Second, any bend or elbow in the channel disrupts the natural flow, resulting in mixing that depends on the cross-section of the channel. In certain embodiments, liquid is forced through the mixer 22 and exits the needle 60. In some embodiments, the outlet port 48 is coupled to the inlet 68, and fluid from the syringe 40 is forced through the dried drug in the mixer 22, thereby dissolving, solubilizing, and / or reconstituting the dried drug.In some embodiments, the dry pharmaceutical composition is separated from the liquid by a structure (e.g., including a seal, a membrane, one or more valves, or other systems, or any combination thereof) that keeps the dry pharmaceutical composition dry until it is mixed with the liquid (e.g., by rupturing or piercing a seal or membrane and / or by opening one or more valves to connect the liquid component with the dry pharmaceutical composition) prior to injection into a subject. The system illustrated in FIG. 2 is non-limiting, and the compositions described herein can be used in conjunction with any suitable injection system (e.g., a system in which a dry pharmaceutical composition comprising a pharmaceutical and a pH adjuster is separated from a liquid component, and the liquid component and dry pharmaceutical composition are mixed prior to injection). In some embodiments, the injection system includes one or more features to increase physical mixing of the pharmaceutical composition and the liquid component to facilitate dissolution. However, in some embodiments, sufficient mixing occurs when the liquid component is contacted with the dry pharmaceutical composition.

[0074] In certain embodiments, a powdered medicament comprising epinephrine and at least one powdered pH adjusting agent (e.g., a buffering agent) is placed in a first chamber of a syringe / auto-injector device. In certain embodiments, the buffering agent is sodium citrate, sodium acetate, potassium citrate, potassium acetate, sodium succinate, or potassium succinate. In some embodiments, a first liquid comprising a solvent (e.g., water) and a pH optimizing agent (e.g., an acid) is placed in a second chamber. In some embodiments, the pH optimizing agent is HCl.

[0075] Prior to administration, the pharmaceutical composition in the first chamber of the medical device is contacted with a first fluid in a second chamber to form a solution for injection. In certain embodiments, the contacting is performed in the first chamber. In certain embodiments, the contacting is performed in the second chamber. In certain embodiments, the contacting is performed in a third chamber. In certain embodiments, the pharmaceutical composition and the first fluid are partially mixed. In certain embodiments, the pharmaceutical composition and the first fluid are thoroughly mixed to form a solution. In certain embodiments, epinephrine is placed in the first chamber and contacted with the acidic first fluid from the second chamber at a pH of about 2.2 or less. In certain embodiments, following dissolution of the epinephrine in the first fluid, a pH adjuster is released to provide a final pH of about 2.2 to about 5.0.

[0076] In some embodiments, the different dissolution rates of the epinephrine and the pH adjuster are achieved by different particle sizes. In some embodiments, the particle size of the epinephrine is smaller relative to the particle size of the pH adjuster, such that the smaller epinephrine particles are more likely to dissolve first and / or more quickly while the pH is initially below 2.2, and the pH adjuster, having a larger particle size, dissolves more slowly, subsequently increasing the pH of the combined solution to a target range of about 2.2 to about 5.0.

[0077] The pharmaceutical compositions provided herein can be administered parenterally, intravenously, intramuscularly, or subcutaneously. In certain embodiments, the route of administration is subcutaneous. In certain embodiments, the route of administration is intravenous.

[0078] Injectable preparations, for example, sterile injectable aqueous or oily suspensions, can be formulated according to known techniques using suitable dispersants or wetting agents and suspending agents.Sterile injectable preparations can be sterile injectable solutions, suspensions or emulsions in non-toxic parenterally acceptable excipients or solvents, for example, as solutions in 1,3-butanediol.Among acceptable vehicles and solvents that can be used are water, Ringer's solution, USP and isotonic sodium chloride solution.

[0079] Injectable preparations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium before use.

[0080] Kits (e.g., drug packs) are also encompassed by the present disclosure. The kits of the present invention may be useful for preventing and / or treating diseases or conditions (e.g., allergic reactions). The provided kits may include the pharmaceutical composition of the present invention and a container (e.g., a vial, an ampoule, a bottle, a syringe, and / or a dispenser package or other suitable container). The provided kits may include the pharmaceutical composition of the present invention in a medical device (e.g., an autoinjector). In certain embodiments, the kits further include instructions for administering the composition.

[0081] In certain embodiments, the therapeutic agent is Agrylin (anagrelide HCl), Akten (lidocaine hydrochloride), Apokyn (apomorphine hydrochloride), Arestin (minocycline hydrochloride), Avandamet (rosiglitazone maleate and metformin HCl), Avelox IV (moxifloxacin hydrochloride), Cardizem® (diltiazem HCl for injection), Contrave (naltrexone HCl and bupropion HCl), Gemzar (gemcitabine HCl), Hycamtin (topotecan hydrochloride), Lamisil (terbinafine hydrochloride), Metozolv ODT (metoclopramide hydrochloride), Namenda (memantine HCl), Paxil (paroxetine hydrochloride), Oxecta (oxycodone HCl), Quillivant XR (methylphenidate hydrochloride), Redux (dexfenfluramine hydrochloride), Relpax (eletriptan hydrobromide), Reminyl (galantamine hydrobromide), Renagel (sevelamer hydrochloride), Requip (ropinirole hydrochloride), Ritalin Selected from the group consisting of LA (methylphenidate HCl), Savella (milnacipran hydrochloride), Strattera (atomoxetine HCl), Tasigna (nilotinib hydrochloride monohydrate), Tiazac (diltiazem hydrochloride), Valcyte (valganciclovir HCl), Valtrex (valacyclovir HCl), VERSED (midazolam HCl), Zanaflex (tizanidine hydrochloride), Zingo (lidocaine hydrochloride monohydrate), ziprasidone (ziprasidone hydrochloride), Zoloft (sertraline HCl), Zometa (zoledronic acid), Zyrtec (cetirizine HCl), glucagon or sumatriptan.

[0082] Pharmaceutically acceptable excipients include any and all excipients, dispersing agents, suspending agents, surfactants, isotonicity agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, etc., that are suitable for the particular dosage form desired. General considerations in the formulation and / or manufacture of pharmaceutical compositions can be found, for example, in Remington's Pharmaceutical Sciences, 16th Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) and Remington: The Science and Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005).

[0083] The provided medical solutions can be delivered intradermally, intramuscularly, intranasally, intravenously, orally, rectally, subcutaneously, topically, or vaginally. In certain embodiments, the provided medical solutions are administered intradermally or intramuscularly. Devices suitable for delivering the intradermal or intramuscular medical solutions described herein include conventional syringes or short needle devices, such as those described in U.S. Patent Nos. 4,886,499, 5,190,521, 5,328,483, 5,527,288, 4,270,537, 5,015,235, 5,141,496, and 5,417,662.

[0084] In some embodiments, the amount of therapeutic agent in the medical solution is an effective amount sufficient to elicit a desired biological response, i.e., treat the condition. In some embodiments, the amount of therapeutic agent in the medical solution is a therapeutically effective amount sufficient to provide a therapeutic benefit in treating the condition or to delay or minimize one or more symptoms associated with the condition. The term "therapeutically effective amount" can encompass an amount that improves overall treatment, reduces or avoids the symptoms or causes of the condition, or enhances the therapeutic effectiveness of another therapeutic agent. In some embodiments, an effective amount is a prophylactically effective amount sufficient to prevent the condition, or one or more symptoms associated with the condition, or prevent its recurrence.

[0085] As used herein, the effective amount of a therapeutic agent will vary from subject to subject, depending on, for example, the species, age and general condition of the subject, the severity of side effects or disorders, the identity of the specific compound, the mode of administration, etc. The desired dosage can be delivered three times a day, twice a day, once a day, every two days, every three days, once a week, once every two weeks, once every three weeks, or once every four weeks. In certain embodiments, the desired dosage can be delivered using multiple administrations (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more administrations).

[0086] In certain embodiments, an effective amount of a compound for one or more daily administrations to a 70 kg adult can include from about 0.0001 mg to about 3000 mg, about 0.0001 mg to about 2000 mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg, about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1 mg to about 1000 mg, about 1 mg to about 100 mg, about 10 mg to about 1000 mg, or about 100 mg to about 1000 mg of compound per unit dosage form.

[0087] In certain embodiments, the compounds of the present invention may be at a dosage level sufficient to deliver from about 0.001 mg / kg to about 100 mg / kg, about 0.01 mg / kg to about 50 mg / kg, preferably about 0.1 mg / kg to about 40 mg / kg, preferably about 0.5 mg / kg to about 30 mg / kg, about 0.01 mg / kg to about 10 mg / kg, about 0.1 mg / kg to about 10 mg / kg, more preferably about 1 mg / kg to about 25 mg / kg of body weight of the subject per day, one or more times per day, to obtain the desired therapeutic effect.

[0088] It will be understood that the dosage ranges as set forth herein provide guidance for administration of the pharmaceutical compositions provided to an adult. For example, the amount to be administered to a child or adolescent can be determined by a medical practitioner or one of ordinary skill in the art and may be less than or the same as the amount administered to an adult.

[0089] In some embodiments, the medical solution is administered to a human subject. In some embodiments, the medical solution is administered to a non-human subject.

[0090] In certain embodiments, the dry medicament or pharmaceutical composition as described herein is stable to changes in temperature. In some embodiments, the dry compositions described herein and / or exemplified in the Examples can be stored at the following temperatures: below -30°C, or -30°C to -25°C, or below -25°C, or -25°C to -20°C, or below -20°C, or -20°C to -15°C, or below -15°C, or -15°C to -10°C, or below -10°C, or -10°C to -5°C, or below -5°C, or -5°C to 0°C, or below 0°C, or 0°C to 5°C, or below 5°C, or 5°C to 10°C, or below 10°C, or 10°C to 15°C, or below 15°C, or 15°C to 20°C, or 20°C. Retains greater than 90% efficacy, greater than 95% efficacy, 90%-100% efficacy or 90%-115% efficacy when subjected to temperature exposure of less than, or 20°C-25°C, or greater than 25°C, or 25°C-30°C, or greater than 30°C, or 30°C-35°C, or greater than 35°C, or 35°C-40°C, or greater than 40°C, or 40°C-45°C, or greater than 45°C, or 45°C-50°C, or greater than 50°C, or 50°C-55°C, or greater than 55°C, or 55°C-60°C or greater than 60°C for up to 1 year, 2 years, 3 years, 5 years, 7 years, up to 10 years or more than 10 years.

[0091] In some embodiments, after dissolving the L-epinephrine powder in the injector device, the resulting solution is prepared from a solution containing L-epinephrine that has previously been kept at a temperature below -30°C, or between -30°C and -25°C, or below -25°C, or between -25°C and -20°C, or below -20°C, or between -20°C and -15°C, or below -15°C, or between -15°C and -10°C, or below -10°C, or between -10°C and -5°C, or below -5°C, or between -5°C and 0°C, or below 0°C, or between 0°C and 5°C, or below 5°C, or between 5°C and 10°C, or below 10°C, or between 10°C and 15°C, or below 15°C, or between 15°C and 20°C. Retains greater than 90% efficacy, greater than 95% efficacy, 90%-100% efficacy or 90%-115% efficacy when subjected to temperature exposure of 0°C, or below 20°C, or between 20°C and 25°C, or above 25°C, or between 25°C and 30°C, or above 30°C, or between 30°C and 35°C, or above 35°C, or between 35°C and 40°C, or above 40°C, or between 40°C and 45°C, or above 45°C, or between 45°C and 50°C, or above 50°C, or between 50°C and 55°C, or above 55°C, or between 55°C and 60°C or above 60°C for up to 1 year, 2 years, 3 years, 5 years, 7 years, up to 10 years or more than 10 years.

[0092] In certain embodiments, a dry medicament or pharmaceutical composition as described herein comprises a chiral therapeutic agent. In certain embodiments, a dry medicament or pharmaceutical composition as described herein comprises chiral L-epinephrine. In some embodiments, a dry pharmaceutical composition as described herein can be maintained at temperatures below -30°C, or between -30°C and -25°C, or below -25°C, or between -25°C and -20°C, or below -20°C, or between -20°C and -15°C, or below -15°C, or between -15°C and -10°C, or below -10°C, or between -10°C and -5°C, or below -5°C, or between -5°C and 0°C, or below 0°C, or between 0°C and 5°C, or below 5°C, or between 5°C and 10°C, or below 10°C, or between 10°C and 15°C, or below 15°C, or between 15°C and 20°C, or below 20°C, or between 20°C and 25°C, or retains greater than 60%, greater than 70%, greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 95%, 95% to 100% chiral purity of L-epinephrine when subjected to temperature exposure of greater than 25°C, or between 25°C and 30°C, or between 30°C and 35°C, or between 35°C and 40°C, or between 40°C and 45°C, or between 45°C and 50°C, or between 50°C and 55°C, or between 55°C and 60°C, or greater than 60°C, for up to 1 year, 2 years, 3 years, 5 years, 7 years, up to 10 years or more than 10 years.

[0093] In some embodiments, after dissolving the L-epinephrine powder in the injector device, the resulting solution is prepared when the dry L-epinephrine was previously kept at a temperature below -30°C, or between -30°C and -25°C, or below -25°C, or between -25°C and -20°C, or below -20°C, or between -20°C and -15°C, or below -15°C, or between -15°C and -10°C, or below -10°C, or between -10°C and -5°C, or below -5°C, or between -5°C and 0°C, or below 0°C, or between 0°C and 5°C, or below 5°C, or between 5°C and 10°C, or below 10°C, or between 10°C and 15°C, or below 15°C, or between 15°C and 20°C, or or less than 20°C, or between 20°C and 25°C, or above 25°C, or between 25°C and 30°C, or above 30°C, or between 30°C and 35°C, or above 35°C, or between 35°C and 40°C, or above 40°C, or between 40°C and 45°C, or above 45°C, or between 45°C and 50°C, or above 50°C, or between 50°C and 55°C, or above 55°C, or between 55°C and 60°C, or above 60°C, for up to 1 year, 2 years, 3 years, 5 years, 7 years, up to 10 years, or more than 10 years. Equivalents and Scope

[0094] In the claims, articles such as "a," "an," and "the" can mean one or more, unless specified to the contrary or clear from the context. A claim or description including "or" between one or more members of a group is considered to be satisfied when one, more than one, or all of the group members are present in, used in, or relevant to a given product or process, unless specified to the contrary or clear from the context. The present disclosure includes embodiments in which exactly one member of the group is present in, used in, or relevant to a given product or process. The present disclosure includes embodiments in which more than one or all of the group members are present in, used in, or relevant to a given product or process.

[0095] Furthermore, the present disclosure encompasses all modifications, combinations, and permutations where one or more limitations, elements, clauses, and descriptive terms from one or more of the claims listed are introduced into another claim. For example, any claim dependent on another claim can be modified to include one or more limitations found in any other claim dependent on the same base claim. Where elements are presented as a list, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element can be extracted from the group. In general, when a disclosure or aspects of a disclosure are referred to as including certain elements and / or features, it should be understood that certain embodiments of the disclosure or aspects of the disclosure consist of or consist essentially of such elements and / or features. For the sake of brevity, those embodiments have not been specifically set forth in this specification. It should also be noted that the terms "comprising" and "containing" are intended to be open-ended, permitting the inclusion of additional elements or steps. Where ranges are given, the terminology is inclusive. Furthermore, unless otherwise specified or apparent from the context and the understanding of one of ordinary skill in the art, values ​​expressed as ranges can assume any particular value or subrange within the stated range in different embodiments of the disclosure, to the tenth of the unit of the lower limit of that range, unless otherwise clearly dictated by the context.

[0096] This application references various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. In the event of a conflict between any of the incorporated references and this specification, this specification shall control. Furthermore, any specific embodiment of the present disclosure that falls within the prior art may be expressly excluded from any one or more of the claims. Such embodiments may be excluded even if the exclusion is not expressly set forth herein, since such embodiments are deemed to be known to those skilled in the art. Any specific embodiment of the present disclosure may be excluded from any claim for any reason, whether or not related to the existence of prior art.

[0097] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. The scope of the embodiments described herein is not limited to the above description, but rather is as set forth in the appended claims. Those skilled in the art will understand that various changes and modifications can be made to the description without departing from the spirit or scope of the present disclosure as defined in the following claims.

Claims

1. An automatic injector, comprising: a first chamber containing a dry pharmaceutical composition, wherein the dry pharmaceutical composition comprises a mixture of a therapeutically effective amount of dry epinephrine and one or more dry pH adjusting agents; and a second chamber containing a first liquid, wherein said first liquid is an acidic aqueous solution having a pH of 0.1 to 6.0; Including, wherein said dry epinephrine and said one or more dry pH adjusting agents are in different particles; wherein the particles of dry epinephrine dissolve faster than the particles of the one or more dry pH adjusters when mixed with the first liquid. Automatic injector.

2. An automatic injector as described in claim 1, wherein the dry epinephrine is more soluble in acid than the one or more dry pH adjusters.

3. An automatic injector as described in claim 1, wherein the dried epinephrine is in particles smaller than the one or more dried pH adjusters.

4. An automatic injector as described in claim 3, wherein the particles of dried epinephrine have a size of about 1 μm to about 30 μm.

5. An automatic injector as described in claim 3, wherein the particles of the one or more dry pH adjusters have a size of about 35 μm to about 100 μm.

6. An automatic injector as described in claim 1, wherein the one or more dry pH adjusters are coated with one or more layers of a pharmaceutically acceptable carrier or one or more layers of a pharmaceutically acceptable polymer.

7. The automatic injector of claim 1, wherein the first liquid is an acid, the acid being HCl, phosphoric acid or sulfuric acid.

8. The automatic injector of claim 1, wherein the dried epinephrine is soluble at a pH of about 0.5 to 6.

9.

9. The automatic injector of claim 1, wherein the one or more dry pH adjusters are selected from the group consisting of sodium and potassium buffering agents.

10. The automatic injector of claim 1, wherein the dried epinephrine is epinephrine in free base form.

11. The automatic injector of claim 1, wherein the one or more dry pH adjusters include sodium citrate.

12. The automatic injector of claim 1, wherein the dry epinephrine is 5 to 10% by weight of the dry pharmaceutical composition and the one or more dry pH adjusters are 90 to 95% by weight of the dry pharmaceutical composition.

13. The automatic injector of claim 1, wherein the acid comprises HCl at a pH of 0.5 to 2.

0.

14. The automatic injector of claim 1, wherein the composition is an amorphous solid or a porous matrix.

15. A method for preparing an epinephrine solution, comprising the step of mixing the dry pharmaceutical composition in the automatic injector of claim 1 with the first liquid.

16. The method of claim 15, wherein the first liquid is sterilized.

17. The method of claim 15, wherein the first liquid comprises one solvent.

18. The method of claim 17, wherein the first liquid comprises water.

19. The method of claim 15, wherein the pH adjuster is sodium citrate, sodium acetate, potassium citrate or potassium acetate.

20. The method of claim 15, wherein the first liquid comprises water and an acid.

21. The method of claim 15, wherein the dry epinephrine forms a readily solubilized salt when mixed with the first liquid.

Images